Prepn: O. Dalmer, E. Walter, DE 632257 (1936 to E. Merck); eidem, US 2149279 (1939 to Merck & Co.); S. A. Hall, P. E. Spoerri, J. Am. Chem. Soc. 62, 664 (1940). Structure-activity study: S. Kushner et al., ibid. 74, 3617 (1952). Pharmacology: I. M. Weiner, J. P. Tinker, J. Pharmacol. Exp. Ther. 180, 411 (1972). HPLC determn in biological samples: J. E. Conte, Jr. et al., J. Chromatogr. Sci. 38, 33 (2000). Clinical pharmacokinetics: C. A. Peloquin et al., Pharmacotherapy 18, 1205 (1998). Clinical trial in combination with rifampicin and isoniazid, q.q.v.: S. K. Teo, Int. J. Tuberc. Lung Dis. 3, 126 (1999); in prevention of tuberculosis: F. Gordin et al., J. Am. Med. Assoc. 283, 1445 (2000). Comprehensive description: E. Feldner, D. Pitre, Anal. Profiles Drug Subs. 12, 433-462 (1983). Review of clinical experience: M. A. Steele, R. M. Des Prez, Chest 94, 845-850 (1988).
Antibacterial (tuberculostatic).
Antibacterial (Tuberculostatic)